New eye injection could reduce treatment frequency for wet AMD

NCT ID NCT07587515

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This early-stage trial tests a new medicine called EYC-0305, given as an eye injection every 24 weeks, in 30 people aged 50 and older with wet age-related macular degeneration (AMD). The main goal is to check if the treatment is safe and tolerable. Researchers will also measure how the drug moves in the body and whether it helps control disease activity and vision.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Bellaire, TX

    RECRUITING

    Bellaire, Texas, 77401, United States

  • Beverly Hills, CA

    RECRUITING

    Beverly Hills, California, 90211, United States

  • Erie, PA

    RECRUITING

    Erie, Pennsylvania, 16505, United States

  • McAllen, TX

    RECRUITING

    McAllen, Texas, 78503, United States

  • The Woodlands, TX

    RECRUITING

    The Woodlands, Texas, 77384, United States